603334 丰倍生物
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)2.37911.45717.87622.69851.945
总资产报酬率 ROA (%)1.8628.12010.82213.04128.438
投入资产回报率 ROIC (%)2.0228.86012.13014.75932.037

边际利润分析
销售毛利率 (%)6.0238.16611.67113.94913.554
营业利润率 (%)4.1504.8556.7428.2868.564
息税前利润/营业总收入 (%)4.4685.0916.9628.4918.186
净利润/营业总收入 (%)3.6904.4326.3567.5077.804

收益指标分析
经营活动净收益/利润总额(%)71.33573.64486.73281.21894.879
价值变动净收益/利润总额(%)0.5710.357-0.038-2.787-3.508
营业外收支净额/利润总额(%)-0.384-0.2982.3010.865-2.002

偿债能力分析
流动比率 (X)4.0333.5122.0371.6881.642
速动比率 (X)2.9382.4491.3621.0981.363
资产负债率 (%)19.62523.61938.88940.13045.254
带息债务/全部投入资本 (%)11.87116.89530.85330.62537.033
股东权益/带息债务 (%)737.702488.624219.454222.155166.539
股东权益/负债合计 (%)409.083323.018157.141149.190120.973
利息保障倍数 (X)13.39920.353112.18763.936-38.919

营运能力分析
应收账款周转天数 (天)12.93217.35717.70716.17520.393
存货周转天数 (天)42.16347.26546.07036.63725.404